Proteomics Preliminary Final Report 2015 and Presentation

31st August 2015, ASX Announcement

Life sciences company Proteomics International Laboratories Ltd  (ASX:PIQ) (the Company, PILL) is pleased to provide the following update on its operations and activities in support of its 2015 Preliminary Final Report released today.

2015 was a transformational year for PILL, highlighted by its successful Initial Public Offering (IPO) and ASX listing and, at the business level, the discovery and reporting of a ground-breaking predictive test for the diagnosis of diabetic kidney disease (DKD).

PILL is focused on the area of proteomics. Proteomics is the industrial scale study of the structure and function of proteins. It is acknowledged as an integral part of biotechnology and life sciences industries and plays a key role in understanding disease and biological systems. PILL is as a global leader in the field, and has developed a propriety technology platform which operates across three synergistic proteomics-based business units each operating in major growth markets. These are:

• Diagnostics: Biomarkers of diseases and personalised medicine.
• Analytical services: Specialist contract research, analytical testing and consultancy.
• Drug discovery: Therapeutic drug discovery with a focus on painkillers and antibiotics.

Financial Overview

Revenue form ordinary activities for the year ending 30 June 2015 continued to reflect growth from previous years, with a year-on-year increase of 27% compared to 2014. Revenue generated in the period largely related to income from the Company’s analytical services business, which will continue to be a key focus moving forward.

Total combined income was $0.97 million (inclusive or R&D Tax incentive and grants), a small reduction relative to the corresponding 2014 figure. It is noted that customer receipts from recent Analytical Services contracts were not fully reflected in the Company’s financial position as at June 30, 2015. The Company reported a loss from ordinary activities for the 2015 year, of $1,149,202, and it is noted that this was impacted by one-off costs associated with the Company’s IPO.

To read the full announcement, please click here. 

To view the presentation, please click here.